National belt quantity of selected varieties, shocked nearly 1/3 do not supply according to the order! Letter from the Health Insurance Bureau

Introduction: The main reason for the shortage of medicines is that enterprises do not supply according to hospital purchase orderson June 4,, Yunnan Medical Security Bureau issued a "Yunnan Medical Security Bureau on the submission of written information notes and capacity list of letters", the document said that in the process of monitoring the procurement of state-belt drugs, found that some selected enterprises failed to supply the selected drugs in accordance with hospital demand in a timely manner, according to which the Yunnan Provincial Medical Security Bureau asked the relevant pharmaceutical manufacturers to submit a written statement and capacity list that can not be supplied normally, and sealed the company's official seal before June 1, if there is no reasonable reason, Yunnan will, in accordance with the relevant provisions, the supply situation into the province's medical insurance credit supervision records and report to the State Joint Management, and in accordance with the provisions of the replacement of the relevant drugs, to ensure the hospital's drug supplyannex shows that there is a shortage of a total of 8 varieties, manufacturers are Suzhou Dongrui, Xing'an Pharmaceutical, Changzhou Four Drugs, Yangzijiang Pharmaceutical Group Jiangsu Pharmaceuticals, State Pharmaceutical Group Rongsheng Pharmaceuticals, Hanyu Pharmaceuticals, Guangzhou Baiyunshan Tianxin Pharmaceuticals, Hunan Warner Pharmaceutical Stakesdocuments reveal that the main reason for the shortage of drugs is that the enterprise did not supply the hospital purchase orderFrom the variety point of view, these shortages are mainly 4 plus 7 band procurement pilot national expansion of the varieties, 25 varieties of 8 drugs can not be supplied according to the order, accounting for nearly 1/3, it is amazingthis is not the first time there has been a problem with the supply of winning symbols in a band purchaseMarch this year, the State Drug Administration issued a notice, said that the State Drug Administration of the United States Celgene Corporation injection yew alcohol (albumin binding type) to carry out on-site inspection of drug production, found that some of the product's key production facilities do not meet the basic requirements of China's drug production quality management, the production process sterile control measures are not in place, not in line with China's "drug production quality management norms (2010 revision) requirements, so the original import of the product was suspendedApril 10, this year, Shanghai Sunshine Pharmaceutical Procurement Network issued "Shanghai on the implementation of the second batch of national organizationdrug centralized procurement results of the work tips (2)," announced that the impact of the outbreak, the second batch of national organizations of drug centralized procurement of 32 varieties, Ogilvy Sataneste tablets, Alyssa tan tablets, polyglycol 4000 loose, hydrochloric acid left-sitrice tablets four varieties may be in the early stages of implementation may be tight supply, delivery delays and other issues, of which omexatineste is expected to gradually resume production capacity in June, normal supplypublic information shows that the four varieties of the winning manufacturers are Huahai Pharmaceuticals, Dongsun Pharmaceuticals, Hunan Warner Pharmaceutical Stakes and Hunan Jiuxian Pharmaceuticalsfor the second batch of shipments to be temporarily unable to supply, the State gave the document a buffer period, allowing the resumption of supply only in June